氨苯砜单疗治愈麻风病人用联合化疗复治后25年随访

25-year follow-up of 657 cured multibacillary leprosy patients retreated with multidrug therapy

目的本文回顾性分析由于氨苯砜（DDS）耐药病人用联合化疗复治情况，并讨论了25a随访后的经验。方法联合化疗复治657例，137例作为对照组。结果620例完成了复治（94．37％），不良反应轻，麻风反应发生率不高，具有良好的顺从性和耐受性。复治组3例复发，累计复发率0．48％，1000人年复发率为0．269，与对照组相比有非常显著差异（P〈0．001）。而且此3例属于晚期复发，最早1例也在DDS单疗后38a、复治后13a复发，而对照组呈现早中期复发，平均潜伏期（6．22＋3．60）a，二者差异明显。结论复治大大地降低了DDS单疗治愈后的复发率，易于接受。作者认为由于持久菌的晚期复发，麻风的防治是一个长期任务。

Objective to analyze retrospectively the role of retreatment on decreasing relapse rate of DDS-cured multibacillary leprosy patients. Methods 657 cases were retreated with multidrug therapy, and 137 cases were as control. Results 620 cases （94.37%） had completed to retreat with mild side effects and lower occurrence rate of leprosy reaction, showing well-compliant and well-tolerated. It was founded that accumulated relapse rate and relapse per person-years revealed statistically significant difference （P〈0.001） between relapsed group and the control. Furthermore, relapse in retreatment group was late relapse but early-medium relapse in the control. Conclusions It was demonstrated that retreatment can greatly reduce the risk of early-medium relapse in DDS-cured patients, and was accepted easily. Due to late relapse, leprosy control is a long-time mission.